Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Average Rating of “Moderate Buy” from Analysts

Jade Biosciences, Inc. (NASDAQ:JBIO) has been given a consensus rating of “Moderate Buy” by the six brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $20.80.

Several equities research analysts have recently commented on JBIO shares. Weiss Ratings restated a “sell (e+)” rating on shares of Jade Biosciences in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Jade Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Guggenheim lifted their target price on shares of Jade Biosciences from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. Finally, HC Wainwright began coverage on Jade Biosciences in a report on Wednesday, January 7th. They issued a “buy” rating and a $25.00 target price on the stock.

Institutional Trading of Jade Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in JBIO. Russell Investments Group Ltd. lifted its position in Jade Biosciences by 40.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,422 shares of the company’s stock worth $38,000 after buying an additional 1,279 shares in the last quarter. Legal & General Group Plc acquired a new stake in Jade Biosciences in the 2nd quarter valued at about $29,000. BNP Paribas Financial Markets bought a new position in shares of Jade Biosciences in the second quarter worth about $32,000. Ameritas Investment Partners Inc. bought a new position in shares of Jade Biosciences in the second quarter worth about $33,000. Finally, New York State Common Retirement Fund lifted its position in shares of Jade Biosciences by 4,180.3% during the third quarter. New York State Common Retirement Fund now owns 5,222 shares of the company’s stock worth $45,000 after purchasing an additional 5,100 shares in the last quarter.

Jade Biosciences Trading Up 0.3%

JBIO stock opened at $14.51 on Wednesday. Jade Biosciences has a 1-year low of $6.57 and a 1-year high of $100.10. The business’s 50 day moving average is $15.03 and its 200-day moving average is $11.06. The firm has a market cap of $715.49 million, a P/E ratio of -1.30 and a beta of 1.02.

Jade Biosciences (NASDAQ:JBIO) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.09.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.